GlassScriptPhysician profile
Luis C Devenecia
NPI 1750495792
$3,936.38
in general payments reported to CMS, 2019-2025
32 companies · $967 in 2025
The $967 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $411 · 2021: $642 · 2022: $358 · 2023: $762 · 2024: $601 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $839.45 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $448.84 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $325.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $266.44 | 2023-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $233.45 | 2019-2025 | Invega Sustenna, Spravato |
| Novartis Pharmaceuticals Corporation | $219.52 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $190.59 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.23 | 2023-2025 | Caplyta |
| Dexcom, INC. | $137.98 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $131.70 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $126.51 | 2019-2025 | |
| Braeburn INC. | $112.18 | 2024-2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $88.02 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.93 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $70.86 | 2023-2025 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $69.60 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.85 | 2023-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $53.80 | 2019-2022 | |
| Hologic Sales and Service, LLC | $49.63 | 2023-2025 | Aptima |
| Agile Therapeutics, INC. | $46.28 | 2021 | |
| Mylan Specialty L.P. | $44.85 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $35.79 | 2024 | Eliquis |
| Insulet Corporation | $22.17 | 2023 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $21.12 | 2023 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $20.27 | 2022 | |
| Eisai INC. | $17.08 | 2021 | |
| Alvogen INC | $16.76 | 2024 | Teriparatide |
| Axsome Therapeutics, INC. | $15.87 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $13.18 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.63 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.19 | 2021 | |
| Gilead Sciences, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Devenecia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.